The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-18 and is reviewed periodically as new material appears.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Most animals and plants can synthesize vitamin C through a sequence of enzyme-driven steps, which convert monosaccharides to vitamin C. However, some mammals have lost the ability to synthesize vitamin C, notably simians and tarsiers. These make up one of two major primate suborders, haplorrhini, and this group includes humans. The strepsirrhini (non-tarsier prosimians) can make their vitamin C, and these include lemurs, lorises, pottos, and galagos. Ascorbic acid is also not synthesized by at least two species of caviidae, the capybara and the guinea pig. Certain birds and fish do not synthesize their vitamin C. All species that do not synthesize ascorbate require it in the diet. Deficiency causes scurvy in humans, and somewhat similar symptoms in other animals. Animals that can contract scurvy all lack the L-gulonolactone oxidase (GULO) enzyme, which is required in the last step of vitamin C synthesis. The genomes of these species contain GULO as pseudogenes, which serve as insight into the evolutionary past of the species.
==== Papillary region ==== The papillary region is composed of loose areolar connective tissue. It is named for its finger-like projections called papillae, which extend toward the epidermis. The papillae provide the dermis with a "bumpy" surface that interdigitates with the epidermis, strengthening the connection between the two layers of skin. In the palms, fingers, soles, and toes, the influence of the papillae projecting into the epidermis forms contours in the skin's surface. These epidermal ridges occur in patterns (see: fingerprint) that are genetically and epigenetically determined and are therefore unique to the individual, making it possible to use fingerprints or footprints as a means of identification.
=== Canada === Under the regulation of the Canadian Food Inspection Agency, manufacturers can produce blue cheese with a maximum of 47 percent moisture and minimum of 27 percent milk fat. Salt is allowed to be used as a preservative; however, the amount of the salt or combination of salts shall not exceed 200 parts per million of milk and milk products used to make the cheese. The Canadian Food Inspection Agency does not limit the use of bacterial cultures to aid further ripening and flavoring preparations other than cheese flavoring.
Sources: en.wikipedia.org
===== MeSH D08.811.682.690 – oxygenases ===== MeSH D08.811.682.690.416 – dioxygenases MeSH D08.811.682.690.416.277 – catechol 1,2-dioxygenase MeSH D08.811.682.690.416.305 – catechol 2,3-dioxygenase MeSH D08.811.682.690.416.319 – cysteine dioxygenase MeSH D08.811.682.690.416.326 – homogentisate 1,2-dioxygenase MeSH D08.811.682.690.416.328 – 3-hydroxyanthranilate 3,4-dioxygenase MeSH D08.811.682.690.416.330 – 4-hydroxyphenylpyruvate dioxygenase MeSH D08.811.682.690.416.333 – indoleamine-pyrrole 2,3-dioxygenase MeSH D08.811.682.690.416.444 – lipoxygenase MeSH D08.811.682.690.416.444.050 – arachidonate lipoxygenases MeSH D08.811.682.690.416.444.050.055 – arachidonate 5-lipoxygenase MeSH D08.811.682.690.416.444.050.060 – arachidonate 12-lipoxygenase MeSH D08.811.682.690.416.444.050.065 – arachidonate 15-lipoxygenase MeSH D08.811.682.690.416.444.525 – protocatechuate 3,4-dioxygenase MeSH D08.811.682.690.416.722 – tryptophan oxygenase MeSH D08.811.682.690.562 – inositol oxygenase MeSH D08.811.682.690.708 – mixed function oxygenases MeSH D08.811.682.690.708.062 – benzoate 4-monooxygenase MeSH D08.811.682.690.708.125 – catechol oxidase MeSH D08.811.682.690.708.125.500 – monophenol monooxygenase MeSH D08.811.682.690.708.170 – cytochrome p-450 enzyme system MeSH D08.811.682.690.708.170.040 – aryl hydrocarbon hydroxylases MeSH D08.811.682.690.708.170.040.024 – 7-alkoxycoumarin o-dealkylase MeSH D08.811.682.690.708.170.040.050 – aniline hydroxylase MeSH D08.811.682.690.708.170.040.110 – benzopyrene hydroxylase MeSH D08.811.682.690.708.170.040.332 – cytochrome p-450 cyp1a1 MeSH D08.811.682.690.708.170.040.443 – cytochrome p-450 cyp1a2 MeSH D08.811.682.690.708.170.040.499 – cytochrome p-450 cyp2b1 MeSH D08.811.682.690.708.170.040.555 – cytochrome p-450 cyp2d6 MeSH D08.811.682.690.708.170.040.777 – cytochrome p-450 cyp2e1 MeSH D08.811.682.690.708.170.040.888 – cytochrome p-450 cyp3a MeSH D08.811.682.690.708.170.085 – camphor 5-monooxygenase MeSH D08.811.682.690.708.170.500 – alkane 1-monooxygenase MeSH D08.811.682.690.708.170.915 – steroid hydroxylases MeSH D08.811.682.690.708.170.915.050 – aldosterone synthase MeSH D08.811.682.690.708.170.915.099 – aromatase MeSH D08.811.682.690.708.170.915.200 – cholesterol 7 alpha-hydroxylase MeSH D08.811.682.690.708.170.915.212 – cholesterol side-chain cleavage enzyme MeSH D08.811.682.690.708.170.915.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.720 – steroid 11-beta-hydroxylase MeSH D08.811.682.690.708.170.915.730 – steroid 12-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.737 – steroid 16-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.748 – steroid 17-alpha-hydroxylase MeSH D08.811.682.690.708.170.915.760 – steroid 21-hydroxylase MeSH D08.811.682.690.708.292 – dopamine beta-hydroxylase MeSH D08.811.682.690.708.392 – fatty acid desaturases MeSH D08.811.682.690.708.392.312 – beta-carotene 15,15'-monooxygenase MeSH D08.811.682.690.708.392.468 – Linoleoyl-CoA desaturase MeSH D08.811.682.690.708.392.625 – stearoyl-coa desaturase MeSH D08.811.682.690.708.401 – gamma-butyrobetaine dioxygenase MeSH D08.811.682.690.708.410 – heme oxygenase (decyclizing) MeSH D08.811.682.690.708.410.500 – heme oxygenase-1 MeSH D08.811.682.690.708.425 – 4-hydroxybenzoate 3-monooxygenase MeSH D08.811.682.690.708.557 – kynurenine 3-monooxygenase MeSH D08.811.682.690.708.601 – phenylalanine hydroxylase MeSH D08.811.682.690.708.660 – procollagen-lysine, 2-oxoglutarate 5-dioxygenase MeSH D08.811.682.690.708.673 – procollagen-proline dioxygenase MeSH D08.811.682.690.708.715 – prostaglandin-endoperoxide synthases MeSH D08.811.682.690.708.749 – squalene monooxygenase MeSH D08.811.682.690.708.783 – steroid hydroxylases MeSH D08.811.682.690.708.783.050 – aldosterone synthase MeSH D08.811.682.690.708.783.099 – aromatase MeSH D08.811.682.690.708.783.200 – cholesterol 7 alpha-hydroxylase MeSH D08.811.682.690.708.783.212 – cholesterol side-chain cleavage enzyme MeSH D08.811.682.690.708.783.400 – 25-hydroxyvitamin d3 1-alpha-hydroxylase MeSH D08.811.682.690.708.783.720 – steroid 11-beta-hydroxylase MeSH D08.811.682.690.708.783.730 – steroid 12-alpha-hydroxylase MeSH D08.811.682.690.708.783.737 – steroid 16-alpha-hydroxylase MeSH D08.811.682.690.708.783.745 – steroid 17-alpha-hydroxylase MeSH D08.811.682.690.708.783.760 – steroid 21-hydroxylase MeSH D08.811.682.690.708.826 – trans-cinnamate 4-monooxygenase MeSH D08.811.682.690.708.870 – tryptophan hydroxylase MeSH D08.811.682.690.708.923 – tyrosine 3-monooxygenase
=== Multidisciplinary doctoral programme === Has been instituted for students who have completed masters in any relevant discipline of natural sciences, medicine, engineering and other related sciences. RCB recruits Junior Research Fellowships (JRFs) twice during an academic year and already mentors 31 Research Fellows.
==== Molecular and signaling response to LTP-inducing stimuli ==== The mechanism for LTP has long been a topic of debate, but, recently, mechanisms have come to some consensus. AMPARs play a key role in this process, as one of the key indicators of LTP induction is the increase in the ratio of AMPAR to NMDARs following high-frequency stimulation. The idea is that AMPARs are trafficked from the dendrite into the synapse and incorporated through some series of signaling cascades. AMPARs are initially regulated at the transcriptional level at their 5' promoter regions. There is significant evidence pointing towards the transcriptional control of AMPA receptors in longer-term memory through cAMP response element-binding protein (CREB) and mitogen-activated protein kinases (MAPK). Messages are translated on the rough endoplasmic reticulum (rough ER) and modified there. Subunit compositions are determined at the time of modification at the rough ER. After post-ER processing in the Golgi apparatus, AMPARs are released into the perisynaptic membrane as a reserve waiting for the LTP process to be initiated. The first key step in the process following glutamate binding to NMDARs is the influx of calcium through the NMDA receptors and the resultant activation of Ca2+/calmodulin-dependent protein kinase (CaMKII). Blocking either this influx or the activation of CaMKII prevents LTP, showing that these are necessary mechanisms for LTP. In addition, profusion of CaMKII into a synapse causes LTP, showing that it is a causal and sufficient mechanism.
== Function == Many roles for DSIP have been suggested following research carried out using peptide analogues with a greater molecular stability and through measuring DSIP-like immunological (DSIP-LI) response by injecting DSIP antiserum and antibodies.
Sources: en.wikipedia.org
The Western blot (sometimes called the protein immunoblot), or Western blotting, is a widely used analytical technique in molecular biology and immunogenetics to detect specific proteins in a sample of tissue homogenate or extract, and to visualize, distinguish, and quantify the different proteins in a complicated protein combination. Western blot technique uses three elements to achieve its task of separating a specific protein from a complex: separation by size, transfer of protein to a solid support, and marking target protein using a primary and secondary antibody to visualize. A synthetic or animal-derived antibody (known as the primary antibody) is created that recognizes and binds to a specific target protein. The electrophoresis membrane is washed in a solution containing the primary antibody, before excess antibody is washed off. A secondary antibody is added which recognizes and binds to the primary antibody. The secondary antibody is visualized through various methods such as staining, immunofluorescence, and radioactivity, allowing indirect detection of the specific target protein. Other related techniques include dot blot analysis, quantitative dot blot, immunohistochemistry and immunocytochemistry, where antibodies are used to detect proteins in tissues and cells by immunostaining, and enzyme-linked immunosorbent assay (ELISA). The name Western blot is a play on the Southern blot, a technique for DNA detection named after its inventor, English biologist Edwin Southern. Similarly, detection of RNA is termed as northern blot.
==== Oxidation of biomass ==== Formic acid can also be obtained by aqueous catalytic partial oxidation of wet biomass by the OxFA process. A Keggin-type polyoxometalate (H5PV2Mo10O40) is used as the homogeneous catalyst to convert sugars, wood, waste paper, or cyanobacteria to formic acid and CO2 as the sole byproduct. Yields of up to 53% formic acid can be achieved.
=== Neuroendocrine === KOR agonists increase serum prolactin levels by tonic inhibition of hypothalamic dopaminergic systems. This response occurs following administration of both centrally penetrating and peripherally restricted KOR agonists. Activation of KOR produce diuretic effects through negative regulation of vasopressin, also known as antidiuretic hormone (ADH). This water diuresis is characterized by increased urine volume and decreased urine osmolality without prominent alterations in electrolyte excretion. Both centrally and peripherally acting KOR agonists promote diuresis through mechanisms including decreased antidiuretic hormone secretion from the hypothalamus and posterior pituitary, reduced renal responsiveness to antidiuretic hormone, and modulation of renal sympathetic nerve activity. KOR signaling in renal tissue may also modulate responses to metabolic stress and induce pathophysiological processes in kidney disease. Activation of the receptor increases adrenocorticotropic hormone (ACTH) and cortisol levels in humans and non-human primates through activation of the hypothalamic-pituitary-adrenal axis (HPA). Administration of the selective agonist U50,488 dose-dependently stimulates ACTH and cortisol release, an effect specific to KOR activation and not observed following μ-opioid (MOR) or δ-opioid receptor (DOR) stimulation. KOR exhibits coexpression with oxytocin and vasopressin in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) of the hypothalamus.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.